MOACM
BCRX icon

Mutual of America Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Mutual of America Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-212,781
Closed -$1.08M – 1455
2024
Q1 		$1.08M Sell
212,781
-8,771
-4% -$49.3K 0.01% 1033
2023
Q4 		$1.33M Sell
221,552
-3,771
-2% -$21.9K 0.02% 1015
2023
Q3 		$1.6M Buy
225,323
+5,589
+3% +$40.2K 0.02% 951
2023
Q2 		$1.55M Buy
219,734
+223
+0.1% +$1.79K 0.02% 980
2023
Q1 		$1.83M Sell
219,511
-156,317
-42% -$1.5M 0.02% 932
2022
Q4 		$4.31M Buy
375,828
+169,090
+82% +$2.11M 0.05% 531
2022
Q3 		$2.6M Hold
206,738
– – 0.04% 723
2022
Q2 		$2.19M Sell
206,738
-3,827
-2% -$39.5K 0.03% 838
2022
Q1 		$3.42M Sell
210,565
-1,293
-0.6% -$20.7K 0.04% 730
2021
Q4 		$2.93M Buy
211,858
+28,425
+15% +$376K 0.03% 834
2021
Q3 		$2.64M Buy
+183,433
New +$2.89M 0.03% 855

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Mutual of America Capital Management's BCRX Position: Q2 2024 in Review

Mutual of America Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 212,781 shares — an estimated $1.08M sold.

Mutual of America Capital Management first reported a position in BCRX in Q3 2021 and held it in 11 quarters. The position peaked at $4.31M in Q4 2022. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • Mutual of America Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Mutual of America Capital Management sold 212,781 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $1.08M.
  • Mutual of America Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2021 and held it in 11 quarters.
  • Mutual of America Capital Management's BioCryst Pharmaceuticals position peaked at $4.31M in Q4 2022.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on Mutual of America Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.